• OPEN AN ACCOUNT
Indian Indices
Sensex
85,408.70 -116.14
( -0.14%)
Global Indices
Nasdaq
48,752.17 288.75
(0.60%)
Dow Jones
6,952.35 21.56
(0.31%)
Hang Seng
50,381.79 37.69
(0.07%)
Nikkei 225
9,870.68 -18.54
(-0.19%)
Forex
USD-INR
89.57 -0.04
(-0.05%)
EUR-INR
105.52 0.34
(0.32%)
GBP-INR
120.86 0.52
(0.43%)
JPY-INR
0.57 0.00
(0.60%)

EQUITY - MARKET SCREENER

Sahasra Electronic Solutions Ltd
Industry :  Electronics - Components
BSE Code
ISIN Demat
Book Value()
93258
INE0RBQ01018
90.7562973
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SAHASRA
84.98
705.17
EPS(TTM)
Face Value()
Div & Yield %
3.32
10
0
 

Alembic Pharma receives USFDA approval for Diltiazem hydrochloride tablets
Nov 15,2025

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Cardizem Tablets, 30 mg, 60 mg, 90 mg, and 120 mg, of Bausch Health US, LLC.

Diltiazem hydrochloride tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm.

Alembic has a cumulative total of 230 ANDA approvals (210 final approvals and 20 tentative approvals) from USFDA.